With 77 layoffs, Valeant gets to work squeezing costs from Dendreon

It's no secret that when serial acquirer and cost-cutting enthusiast Valeant ($VRX) takes over a company, layoffs are on the way. And for Dendreon, the bankrupt Seattle biotech whose assets the Canadian company snatched up last month, they've already begun. Seventy-seven employees will pack their bags, according to a WARN notice seen by The Seattle Times. Washington's state Employment Security Department received word of the job cuts Feb. 23, immediately after Valeant wrapped its $400 million buyout of Dendreon's flailing prostate cancer vaccine, Provenge, along with other prospects. "Most of these positions were in G&A functions where there was overlap with Valeant's existing businesses, especially in corporate and back office functions," Valeant spokeswoman Laurie Little told the paper in an email. More

Suggested Articles

Having struck two COVID-19 vaccine supply deals already, EU officials are in discussions with Novavax, as well.

With its phase 3 trial moving right along, Moderna is expecting efficacy data in November—likely after Pfizer and BioNTech, but before everyone else.

BioNTech expects a quick turnaround once the transaction closes and plans to produce up to 250 million doses of BNT162b2 in the first half of 2021.